CC BY-NC-ND 4.0 · Laryngorhinootologie 2021; 100(S 02): S308-S309
DOI: 10.1055/s-0041-1728932
Abstracts
Salivary Glands / Thyroid Gland: Salivary Glands

Trop-2 protein is highly expressed in salivary gland cancers and represents a therapeutic target

P Wolber
1   Universität zu Köln, Medizinische Fakultät, Klinik und Poliklinik für Hals-, Nasen-, Ohren-Heilkunde, Kopf- und Hals- Chirurgie, Köln
,
L Nachtsheim
1   Universität zu Köln, Medizinische Fakultät, Klinik und Poliklinik für Hals-, Nasen-, Ohren-Heilkunde, Kopf- und Hals- Chirurgie, Köln
,
F Hoffmann
2   Friedrich Schiller Universität Jena, Medizinische Fakultät, MALDI Imaging and Innovative Biophotonics, Jena
,
JP Klußmann
1   Universität zu Köln, Medizinische Fakultät, Klinik und Poliklinik für Hals-, Nasen-, Ohren-Heilkunde, Kopf- und Hals- Chirurgie, Köln
,
MF Meyer
3   Universität Duisburg-Essen, Medizinische Fakultät, Klinik und Poliklinik für Hals-, Nasen-, Ohren-Heilkunde, Kopf- und Hals- Chirurgie, Essen
,
F von Eggeling
4   Friedrich-Schiller-Universität Jena, MALDI Imaging, Core Unit Proteome Analysis, DFG Core Unit Jena Biophotonic and Imaging Laboratory (JBIL), Jena
,
O Guntinas-Lichius
5   Friedrich Schiller Universität Jena, Medizinische Fakultät, Klinik und Poliklinik für Hals-, Nasen-, Ohren-Heilkunde, Kopf- und Hals- Chirurgie, Jena
,
A Quaas
6   Universität zu Köln, Medizinische Fakultät, Institut für Pathologie, Köln
,
C Arolt
6   Universität zu Köln, Medizinische Fakultät, Institut für Pathologie, Köln
› Author Affiliations
› Further Information
Also available at
 
 

    Objectives Treatment options for unresectable, recurrent or metastatic salivary gland cancers (SGC) are scarce. Trophoblast cell surface antigen 2 (Trop-2) is involved in tumorigenesis and its potential as a target for the antibody-drug conjugate sacituzumab govitecan has already been demonstrated in a number of different tumor entities. In metastatic triple-negative breast cancer, the United States Food and Drug Administration has already approved this antibody drug conjugate. Here, we aimed to investigate the role of Trop-2 in SGC.

    Materials and methods We retrospectively reviewed the medical records of all patients that underwent surgery for a primary SGC in a tertiary referral center between 1990 and 2014. Immunohistochemical (IHC) staining for Trop-2 was performed. Additionally, cases were analyzed by MALDI-mass spectrometry (MS) imaging to confirm the IHC results.

    Results The cohort consisted of 114 tumors of the parotid gland (90.4%) and submandibular gland (9.6%). It mainly included mucoepidermoid carcinomas, salivary duct carcinomas and adenoid cystic carcinomas. 43.9% showed a high, 37.7% a moderate and 9.6% a low expression of Trop-2 (91.2% Trop-2 positive SGCs in total) with a highly homogenous pattern in all tumors. MALDI-MS imaging confirmed the presence of Trop-2 in all tested tumor samples.

    Conclusion This is the first study to determine the protein expression of Trop-2 in SGC using different techniques. The homogeneous and highly positive expression of Trop-2 in SGC makes it an interesting biomarker and promising target for therapy e.g. with sacituzumab govitecan in future clinical studies for tumors with otherwise limited treatment options.

    Poster-PDF A-1688.pdf


    #

    Conflict of interest

    Der Erstautor gibt keinen Interessenskonflikt an.

    Address for correspondence

    M.D., M.Sc. Wolber Philipp
    Universität zu Köln, Medizinische Fakultät, Klinik und Poliklinik für Hals-, Nasen-, Ohren-Heilkunde, Kopf- und Hals- Chirurgie
    Köln

    Publication History

    Article published online:
    13 May 2021

    © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany